Effect of a tyrosine kinase inhibitor STI571 in a patient with hepatic metastases from a duodenal gastrointestinal stromal tumor

Akira Sawaki; Kazuhiko Ohashi; Kenji Yamao; Ken Ichi Inada; Yasuhiro Shimizu; Akira Matsuura; Tuneya Nakamura; Takashi Suzuki; Kazuo Hara; Kenji Okubo; Ryuzo Ohno

doi:10.1007/s00535-002-1124-1

Effect of a tyrosine kinase inhibitor STI571 in a patient with hepatic metastases from a duodenal gastrointestinal stromal tumor

Akira Sawaki, Kazuhiko Ohashi, Kenji Yamao, Ken Ichi Inada, Yasuhiro Shimizu, Akira Matsuura, Tuneya Nakamura, Takashi Suzuki, Kazuo Hara, Kenji Okubo, Ryuzo Ohno

Gastroenterology

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors. The molecular etiology is the result of mutations in the c-Kit gene. The mutant c-Kit proteins, which are activated without a stem cell factor, contribute to the tumor development. STI571 selectively inhibits c-Kit, BCR-ABL, and PDGFR tyrosine kinases. Based on this potential to inhibit critical c-Kit function in GISTs, case studies have reported effective outcomes following treatment with STI571. This case report describes a highly effective use of STI571 in a 54-year-old woman with multiple liver metastases from a GIST originating in the duodenum.

Original language	English
Pages (from-to)	690-694
Number of pages	5
Journal	Journal of Gastroenterology
Volume	38
Issue number	7
DOIs	https://doi.org/10.1007/s00535-002-1124-1
Publication status	Published - 01-07-2003

All Science Journal Classification (ASJC) codes

Gastroenterology

Access to Document

10.1007/s00535-002-1124-1

Cite this

@article{b8aeb47f34bf40c98cabe0846de72e01,

title = "Effect of a tyrosine kinase inhibitor STI571 in a patient with hepatic metastases from a duodenal gastrointestinal stromal tumor",

abstract = "Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors. The molecular etiology is the result of mutations in the c-Kit gene. The mutant c-Kit proteins, which are activated without a stem cell factor, contribute to the tumor development. STI571 selectively inhibits c-Kit, BCR-ABL, and PDGFR tyrosine kinases. Based on this potential to inhibit critical c-Kit function in GISTs, case studies have reported effective outcomes following treatment with STI571. This case report describes a highly effective use of STI571 in a 54-year-old woman with multiple liver metastases from a GIST originating in the duodenum.",

author = "Akira Sawaki and Kazuhiko Ohashi and Kenji Yamao and Inada, {Ken Ichi} and Yasuhiro Shimizu and Akira Matsuura and Tuneya Nakamura and Takashi Suzuki and Kazuo Hara and Kenji Okubo and Ryuzo Ohno",

year = "2003",

month = jul,

day = "1",

doi = "10.1007/s00535-002-1124-1",

language = "English",

volume = "38",

pages = "690--694",

journal = "Journal of Gastroenterology",

issn = "0944-1174",

publisher = "Springer",

number = "7",

}

TY - JOUR

T1 - Effect of a tyrosine kinase inhibitor STI571 in a patient with hepatic metastases from a duodenal gastrointestinal stromal tumor

AU - Sawaki, Akira

AU - Ohashi, Kazuhiko

AU - Yamao, Kenji

AU - Inada, Ken Ichi

AU - Shimizu, Yasuhiro

AU - Matsuura, Akira

AU - Nakamura, Tuneya

AU - Suzuki, Takashi

AU - Hara, Kazuo

AU - Okubo, Kenji

AU - Ohno, Ryuzo

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors. The molecular etiology is the result of mutations in the c-Kit gene. The mutant c-Kit proteins, which are activated without a stem cell factor, contribute to the tumor development. STI571 selectively inhibits c-Kit, BCR-ABL, and PDGFR tyrosine kinases. Based on this potential to inhibit critical c-Kit function in GISTs, case studies have reported effective outcomes following treatment with STI571. This case report describes a highly effective use of STI571 in a 54-year-old woman with multiple liver metastases from a GIST originating in the duodenum.

AB - Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors. The molecular etiology is the result of mutations in the c-Kit gene. The mutant c-Kit proteins, which are activated without a stem cell factor, contribute to the tumor development. STI571 selectively inhibits c-Kit, BCR-ABL, and PDGFR tyrosine kinases. Based on this potential to inhibit critical c-Kit function in GISTs, case studies have reported effective outcomes following treatment with STI571. This case report describes a highly effective use of STI571 in a 54-year-old woman with multiple liver metastases from a GIST originating in the duodenum.

UR - http://www.scopus.com/inward/record.url?scp=0042062396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042062396&partnerID=8YFLogxK

U2 - 10.1007/s00535-002-1124-1

DO - 10.1007/s00535-002-1124-1

M3 - Article

C2 - 12898363

AN - SCOPUS:0042062396

SN - 0944-1174

VL - 38

SP - 690

EP - 694

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

IS - 7

ER -

Effect of a tyrosine kinase inhibitor STI571 in a patient with hepatic metastases from a duodenal gastrointestinal stromal tumor

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this